These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 10715296)

  • 1. Biologic factors determine prognosis in infants with stage IV neuroblastoma: A prospective Children's Cancer Group study.
    Schmidt ML; Lukens JN; Seeger RC; Brodeur GM; Shimada H; Gerbing RB; Stram DO; Perez C; Haase GM; Matthay KK
    J Clin Oncol; 2000 Mar; 18(6):1260-8. PubMed ID: 10715296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful treatment of stage III neuroblastoma based on prospective biologic staging: a Children's Cancer Group study.
    Matthay KK; Perez C; Seeger RC; Brodeur GM; Shimada H; Atkinson JB; Black CT; Gerbing R; Haase GM; Stram DO; Swift P; Lukens JN
    J Clin Oncol; 1998 Apr; 16(4):1256-64. PubMed ID: 9552023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group Study.
    Schmidt ML; Lal A; Seeger RC; Maris JM; Shimada H; O'Leary M; Gerbing RB; Matthay KK
    J Clin Oncol; 2005 Sep; 23(27):6474-80. PubMed ID: 16116154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Favorable biology and outcome of stage IV-S neuroblastoma with supportive care or minimal therapy: a Children's Cancer Group study.
    Nickerson HJ; Matthay KK; Seeger RC; Brodeur GM; Shimada H; Perez C; Atkinson JB; Selch M; Gerbing RB; Stram DO; Lukens J
    J Clin Oncol; 2000 Feb; 18(3):477-86. PubMed ID: 10653863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study.
    George RE; London WB; Cohn SL; Maris JM; Kretschmar C; Diller L; Brodeur GM; Castleberry RP; Look AT
    J Clin Oncol; 2005 Sep; 23(27):6466-73. PubMed ID: 16116152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. N-Myc gene amplification is a major prognostic factor in localized neuroblastoma: results of the French NBL 90 study. Neuroblastoma Study Group of the Société Francaise d'Oncologie Pédiatrique.
    Rubie H; Hartmann O; Michon J; Frappaz D; Coze C; Chastagner P; Baranzelli MC; Plantaz D; Avet-Loiseau H; Bénard J; Delattre O; Favrot M; Peyroulet MC; Thyss A; Perel Y; Bergeron C; Courbon-Collet B; Vannier JP; Lemerle J; Sommelet D
    J Clin Oncol; 1997 Mar; 15(3):1171-82. PubMed ID: 9060561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes of children with intermediate-risk neuroblastoma after treatment stratified by MYCN status and tumor cell ploidy.
    Bagatell R; Rumcheva P; London WB; Cohn SL; Look AT; Brodeur GM; Frantz C; Joshi V; Thorner P; Rao PV; Castleberry R; Bowman LC
    J Clin Oncol; 2005 Dec; 23(34):8819-27. PubMed ID: 16314642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group.
    Goto S; Umehara S; Gerbing RB; Stram DO; Brodeur GM; Seeger RC; Lukens JN; Matthay KK; Shimada H
    Cancer; 2001 Nov; 92(10):2699-708. PubMed ID: 11745206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biologic variables in the outcome of stages I and II neuroblastoma treated with surgery as primary therapy: a children's cancer group study.
    Perez CA; Matthay KK; Atkinson JB; Seeger RC; Shimada H; Haase GM; Stram DO; Gerbing RB; Lukens JN
    J Clin Oncol; 2000 Jan; 18(1):18-26. PubMed ID: 10623689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significance of clinical and biologic features in Stage 3 neuroblastoma: a report from the International Neuroblastoma Risk Group project.
    Meany HJ; London WB; Ambros PF; Matthay KK; Monclair T; Simon T; Garaventa A; Berthold F; Nakagawara A; Cohn SL; Pearson AD; Park JR
    Pediatr Blood Cancer; 2014 Nov; 61(11):1932-9. PubMed ID: 25044743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enlarged and prominent nucleoli may be indicative of MYCN amplification: a study of neuroblastoma (Schwannian stroma-poor), undifferentiated/poorly differentiated subtype with high mitosis-karyorrhexis index.
    Kobayashi C; Monforte-Munoz HL; Gerbing RB; Stram DO; Matthay KK; Lukens JN; Seeger RC; Shimada H
    Cancer; 2005 Jan; 103(1):174-80. PubMed ID: 15549714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuroblastoma of undifferentiated subtype, prognostic significance of prominent nucleolar formation, and MYC/MYCN protein expression: a report from the Children's Oncology Group.
    Wang LL; Suganuma R; Ikegaki N; Tang X; Naranjo A; McGrady P; London WB; Hogarty MD; Gastier-Foster JM; Look AT; Park JR; Maris JM; Cohn SL; Seeger RC; Shimada H
    Cancer; 2013 Oct; 119(20):3718-26. PubMed ID: 23901000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Significance of MYCN amplification in international neuroblastoma staging system stage 1 and 2 neuroblastoma: a report from the International Neuroblastoma Risk Group database.
    Bagatell R; Beck-Popovic M; London WB; Zhang Y; Pearson AD; Matthay KK; Monclair T; Ambros PF; Cohn SL;
    J Clin Oncol; 2009 Jan; 27(3):365-70. PubMed ID: 19047282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MYCN protein expression as a predictor of neuroblastoma prognosis.
    Chan HS; Gallie BL; DeBoer G; Haddad G; Ikegaki N; Dimitroulakos J; Yeger H; Ling V
    Clin Cancer Res; 1997 Oct; 3(10):1699-706. PubMed ID: 9815553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Long-term follow-up of neuroblastoma in children less than 18 months of age].
    Zhao J; Pan C; Xu M; Zhou M; Gao YJ; Hu WT; Tang JY
    Zhonghua Er Ke Za Zhi; 2017 Oct; 55(10):754-759. PubMed ID: 29050113
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical significance of MYCN amplification and ploidy in favorable-stage neuroblastoma: a report from the Children's Oncology Group.
    Schneiderman J; London WB; Brodeur GM; Castleberry RP; Look AT; Cohn SL
    J Clin Oncol; 2008 Feb; 26(6):913-8. PubMed ID: 18281664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Consolidation chemoradiotherapy and autologous bone marrow transplantation versus continued chemotherapy for metastatic neuroblastoma: a report of two concurrent Children's Cancer Group studies.
    Stram DO; Matthay KK; O'Leary M; Reynolds CP; Haase GM; Atkinson JB; Brodeur GM; Seeger RC
    J Clin Oncol; 1996 Sep; 14(9):2417-26. PubMed ID: 8823319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MYCN expression is not prognostic of adverse outcome in advanced-stage neuroblastoma with nonamplified MYCN.
    Cohn SL; London WB; Huang D; Katzenstein HM; Salwen HR; Reinhart T; Madafiglio J; Marshall GM; Norris MD; Haber M
    J Clin Oncol; 2000 Nov; 18(21):3604-13. PubMed ID: 11054433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intensified chemotherapy increases the survival rates in patients with stage 4 neuroblastoma with MYCN amplification.
    Kaneko M; Tsuchida Y; Mugishima H; Ohnuma N; Yamamoto K; Kawa K; Iwafuchi M; Sawada T; Suita S
    J Pediatr Hematol Oncol; 2002 Nov; 24(8):613-21. PubMed ID: 12439032
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natural history and biology of stage A neuroblastoma: a Pediatric Oncology Group Study.
    Alvarado CS; London WB; Look AT; Brodeur GM; Altmiller DH; Thorner PS; Joshi VV; Rowe ST; Nash MB; Smith EI; Castleberry RP; Cohn SL
    J Pediatr Hematol Oncol; 2000; 22(3):197-205. PubMed ID: 10864050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.